Long‐acting injectable cabotegravir: implementation science needed to advance this additional HIV prevention choice

The United States Food and Drug Administration, the first regulatory authority to approve CAB-LA, recommends nucleic acid amplification testing (NAAT) prior to initiation and follow-up. [...]as confirmatory HIV testing is required for diagnosis, earlier detection with NAAT may not result in an earli...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the International AIDS Society 2022-07, Vol.25 (7), p.n/a
Main Authors: Schmidt, Heather‐Marie Ann, Rodolph, Michelle, Schaefer, Robin, Baggaley, Rachel, Doherty, Meg
Format: Article
Language:English
Subjects:
Acquired immune deficiency syndrome
AIDS
Algorithms
Antiretroviral drugs
Breastfeeding & lactation
Disease prevention
Drug resistance
Gender
HIV
HIV infection
Human immunodeficiency virus
Infections
Medical tests
Nucleic acids
Prevention
Regulatory approval
Transgender persons
Viewpoint
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The United States Food and Drug Administration, the first regulatory authority to approve CAB-LA, recommends nucleic acid amplification testing (NAAT) prior to initiation and follow-up. [...]as confirmatory HIV testing is required for diagnosis, earlier detection with NAAT may not result in an earlier diagnosis. [...]NAATs are not readily available in many LMICs, as most do not have regulatory approval for HIV diagnosis.Comparatively long turnaround times and higher costs limit the feasibility of this approach. The risk of delayed identification of HIV infection and potential increase in HIV drug resistance (theoretically prevented with NAAT) must be balanced with the benefits of wider CAB-LA access and decreasing new HIV infections (using current national testing algorithms).
ISSN:1758-2652
1758-2652
DOI:10.1002/jia2.25963